Insights

Strategic funding Leverage Cardurion’s substantial funding and high-profile investor backing (including Bain Capital and a $260M Series B) to position partnerships, co-development, or milestone-driven collaborations with large pharma or biotech players looking to accelerate cardiovascular programs.

Cardiovascular focus Target opportunities in heart failure and other cardiovascular diseases where PDE9 and CaMKII inhibition programs are advancing, aligning outreach with Cardurion’s core therapeutic areas and highlighting potential for enabling diagnostics, companion therapies, or combo regimens.

Global footprint Capitalize on Cardurion’s dual presence in the U.S. and Japan to explore regional collaborations, JV opportunities, or cross-border research partnerships that leverage local regulatory routes, clinical trial capabilities, and market access considerations.

Leadership moves Engage with Cardurion’s growing leadership team, especially recent hires in people operations and business development, to discuss talent-plugged initiatives, strategic partnerships, and co-investment opportunities that require enhanced organizational capacity.

Strategic partnerships Position as a potential strategic investor or collaboration partner to advance Cardurion’s in-house discovery pipeline, offering shared risk, access to complementary platforms, and support for later-stage clinical development and commercial readiness.

Similar companies to Cardurion Pharmaceuticals

Cardurion Pharmaceuticals Tech Stack

Cardurion Pharmaceuticals uses 8 technology products and services including SAS, Amazon Web Services, WordPress, and more. Explore Cardurion Pharmaceuticals's tech stack below.

Media & News

Cardurion Pharmaceuticals's Email Address Formats

Cardurion Pharmaceuticals uses at least 1 email format:
Cardurion Pharmaceuticals Email FormatsExamplePercentage
First.Last@cardurion.comJohn.Doe@cardurion.com
100%

Frequently Asked Questions

What is Cardurion Pharmaceuticals's official website and social media links?

Minus sign iconPlus sign icon
Cardurion Pharmaceuticals's official website is cardurion.com and has social profiles on LinkedIn and Crunchbase.

How much revenue does Cardurion Pharmaceuticals generate?

Minus sign iconPlus sign icon
As of October 2026, Cardurion Pharmaceuticals's annual revenue is estimated to be $25M - $50M.

What is Cardurion Pharmaceuticals's SIC code and NAICS code?

Minus sign iconPlus sign icon
Cardurion Pharmaceuticals's SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Cardurion Pharmaceuticals have currently?

Minus sign iconPlus sign icon
As of October 2026, Cardurion Pharmaceuticals has approximately 75 employees across 2 continents, including North America and Asia. Key team members include Chief Operating Officer - Consultant: R. F., Vice President And Head Of Cardurion Pharmaceuticals, K.K: S. I. and Vice President, Global Program Lead, Head Of Program Leadership: G. B. A. Explore Cardurion Pharmaceuticals's employee directory with LeadIQ.

What industry does Cardurion Pharmaceuticals belong to?

Minus sign iconPlus sign icon
Cardurion Pharmaceuticals operates in the Biotechnology Research industry.

What technology does Cardurion Pharmaceuticals use?

Minus sign iconPlus sign icon
Cardurion Pharmaceuticals's tech stack includes SAS, Amazon Web Services, WordPress, DocuSign, Cisco, Smartsheet, Slack and Box.

What is Cardurion Pharmaceuticals's email format?

Minus sign iconPlus sign icon
Cardurion Pharmaceuticals's email format typically follows the pattern of First.Last@cardurion.com. Find more Cardurion Pharmaceuticals email formats with LeadIQ.

How much funding has Cardurion Pharmaceuticals raised to date?

Minus sign iconPlus sign icon
As of October 2026, Cardurion Pharmaceuticals has raised $603M in funding. The last funding round occurred on Jul 16, 2024 for $260M.

When was Cardurion Pharmaceuticals founded?

Minus sign iconPlus sign icon
Cardurion Pharmaceuticals was founded in 2017.
Cardurion Pharmaceuticals logo

Cardurion Pharmaceuticals

Biotechnology ResearchMassachusetts, United States51-200 Employees

Cardurion Pharmaceuticals operates in the biotechnology research space with a focus on cardiovascular disease, aiming to discover and develop novel therapies for heart failure and related conditions. It is advancing clinical programs targeting PDE9 inhibition and CaMKII inhibition. The organization pursues a strategic portfolio approach rooted in in-house drug discovery and an office of strategy to coordinate its pipeline. Foundational partnerships with strategic collaborators help support its development efforts.

Headquartered in Burlington, Massachusetts, Cardurion maintains additional facilities in Shonan, Japan, and employs a mid-sized team. In 2025, the company announced leadership additions as part of its ongoing organizational development.

Section iconCompany Overview

SIC Code
8731 - Commercial Physical and Biological Research
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2017
Employees
51-200

Section iconFunding & Financials

  • $603M

    Cardurion Pharmaceuticals has raised a total of $603M of funding over 6 rounds. Their latest funding round was raised on Jul 16, 2024 in the amount of $260M as a Series B.

  • $25M - $50M

    Cardurion Pharmaceuticals's revenue is estimated to be in the range of $25M - $50M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.